<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">34402459</PMID><DateCompleted><Year>2022</Year><Month>01</Month><Day>28</Day></DateCompleted><DateRevised><Year>2022</Year><Month>06</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1473-6551</ISSN><JournalIssue CitedMedium="Internet"><Volume>34</Volume><Issue>5</Issue><PubDate><Year>2021</Year><Month>Oct</Month><Day>01</Day></PubDate></JournalIssue><Title>Current opinion in neurology</Title><ISOAbbreviation>Curr Opin Neurol</ISOAbbreviation></Journal><ArticleTitle>Amyotrophic lateral sclerosis is a systemic disease: peripheral contributions to inflammation-mediated neurodegeneration.</ArticleTitle><Pagination><StartPage>765</StartPage><EndPage>772</EndPage><MedlinePgn>765-772</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/WCO.0000000000000983</ELocationID><Abstract><AbstractText Label="PURPOSE OF REVIEW">Neuroinflammation is an important mediator of the pathogenesis of disease in amyotrophic lateral sclerosis (ALS). Genetic mutations such as C9orf72 have begun to define the numerous cell autonomous pathways that initiate motor neuron injury. Yet, it is the signalling to surrounding glia and peripherally derived immune cells that initiates the noncell autonomous inflammatory process and promotes self-propagating motor neuron cell death. The purpose of this review is to explore the systemic immune/inflammatory contributions to the pathogenesis of ALS: what are the peripheral pro-inflammatory signatures, what initiates their presence and do they represent potential therapeutic targets.</AbstractText><AbstractText Label="RECENT FINDINGS">In ALS, motor neuron cell death is initiated by multiple cell autonomous pathways leading to misfolded proteins, oxidative stress, altered mitochondria, impaired autophagy and altered RNA metabolism, which collectively promote noncell autonomous inflammatory reactivity. The resulting disease is characterized by activated microglia and astrocytes as well as peripherally derived pro-inflammatory innate and adaptive immune cells. In this unrelenting disorder, circulating blood monocytes and natural killer cells are pro-inflammatory. Furthermore, regulatory T lymphocytes are dysfunctional, and pro-inflammatory cytokines and acute phase proteins are elevated.</AbstractText><AbstractText Label="SUMMARY">The collective dysregulation of cells and cytokines in patients with ALS accurately reflect increased disease burdens, more rapid progression rates and reduced survival times, reinforcing the concept of ALS as a disorder with extensive systemic pro-inflammatory responses. These increased systemic pro-inflammatory immune constituents provide potentially meaningful therapeutic targets.</AbstractText><CopyrightInformation>Copyright &#xa9; 2021 Wolters Kluwer Health, Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Appel</LastName><ForeName>Stanley H</ForeName><Initials>SH</Initials><AffiliationInfo><Affiliation>Peggy and Gary Edwards ALS Laboratory, Stanley H. Appel Department of Neurology, Houston Methodist Neurological Institute, Houston Methodist Research Institute, Houston, Texas, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beers</LastName><ForeName>David R</ForeName><Initials>DR</Initials></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Weihua</ForeName><Initials>W</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Curr Opin Neurol</MedlineTA><NlmUniqueID>9319162</NlmUniqueID><ISSNLinking>1350-7540</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016207">Cytokines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009046" MajorTopicYN="N">Motor Neurons</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000090862" MajorTopicYN="N">Neuroinflammatory Diseases</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>8</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>1</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>8</Month><Day>17</Day><Hour>8</Hour><Minute>46</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34402459</ArticleId><ArticleId IdType="doi">10.1097/WCO.0000000000000983</ArticleId><ArticleId IdType="pii">00019052-202110000-00021</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Beers DR, Appel SH. Immune dysregulation in amyotrophic lateral sclerosis:mechanisms and emerging therapies. Lancet Neurol 2019; 18:211&#x2013;220.</Citation></Reference><Reference><Citation>Kano O, Tanaka K, Kanno T, et al. Neuronal apoptosis inhibitory protein is implicated in amyotrophic lateral sclerosis symptoms. Sci Rep 2018; 8:6.</Citation></Reference><Reference><Citation>Kim BW, Jeong YE, Wong M, Martin LJ. DNA damage accumulates and responses are engaged in human ALS brain and spinal motor neurons and DNA repair is activatable in iPSC-derived motor neurons with SOD1 mutations. Acta Neuropathol Commun 2020; 8:7.</Citation></Reference><Reference><Citation>Ito Y, Ofengeim D, Najafov A, et al. RIPK1 mediates axonal degeneration by promoting inflammation and necroptosis in ALS. Science 2016; 353:603&#x2013;608.</Citation></Reference><Reference><Citation>Morrice JR, Gregory-Evans CY, Shaw CE. Necroptosis in amyotrophic lateral sclerosis and other neurological disorders. Biochim Biophys Acta 2017; 1863:347&#x2013;353.</Citation></Reference><Reference><Citation>Mifflin L, Hu Z, Dufort C, et al. A RIPK1-regulated inflammatory microglial state in amyotrophic lateral sclerosis. Proc Natl Acad Sci U S A 2021; 118:e2025102118.</Citation></Reference><Reference><Citation>Chevin M, S&#xe9;bire G. Cell Necroptosis in ALS: a hot topic in-progress. Cell Death Discovery 2021; 7:79.</Citation></Reference><Reference><Citation>Devos D, Moreau C, Kyheng M. A ferroptosis&#x2013;based panel of prognostic biomarkers for amyotrophic lateral sclerosis. Sci Rep 2019; 9:2918.</Citation></Reference><Reference><Citation>Ren JX, Sun X, Yan X-L, et al. Ferroptosis in neurological diseases. Front Cell Neurosci 2020; 14:218.</Citation></Reference><Reference><Citation>McCombe PA, Lee JD, Woodruff TM, Henderson RD. The peripheral immune system and amyotrophic lateral sclerosis. Front Neurol 2020; 11:279.</Citation></Reference><Reference><Citation>Liu Z, Cheng X, Zhong S, et al. Peripheral and central nervous system immune response crosstalk in amyotrophic lateral sclerosis. Front Neurosci 2020; 14:575.</Citation></Reference><Reference><Citation>Hu Y, Cao C, Qin X-Y, et al. Increased peripheral blood inflammatory cytokine levels in amyotrophic lateral sclerosis: a meta-analysis study. Sci Rep 2017; 7:9094.</Citation></Reference><Reference><Citation>Murdock BJ, Zhou T, Kashlan SR, et al. Correlation of peripheral immunity with rapid amyotrophic lateral sclerosis progression. JAMA Neurol 2017; 74:1446&#x2013;1454.</Citation></Reference><Reference><Citation>Zhao W, Beers DR, Hooten KG, et al. Characterization of gene expression phenotype in amyotrophic lateral sclerosis monocytes. JAMA Neurol 2017; 74:677&#x2013;685.</Citation></Reference><Reference><Citation>Du Y, Zhao W, Thonhoff JR, et al. Increased activation ability of monocytes from ALS patients. Exp Neurol 2020; 328:113259.</Citation></Reference><Reference><Citation>Zhao W, Beers DR, Thonhoff JR, et al. Immunosuppressive functions of M2 macrophages derived from iPSCs of patients with ALS and healthy controls. iScience 2020; 23:101192.</Citation></Reference><Reference><Citation>Garofalo S, Cocozza G, Porzia A, et al. Natural killer cells modulate motor neuron-immune cell cross talk in models of amyotrophic lateral sclerosis. Nature Commun 2020; 11:1773.</Citation></Reference><Reference><Citation>Beers DR, Zhao W, Wang J, et al. ALS patients&#x2019; regulatory T lymphocytes are dysfunctional, and correlate with disease progression rate and severity. JCI Insight 2017; 2:e89530.</Citation></Reference><Reference><Citation>Sheean RK, McKay FC, Cretney E, et al. Association of regulatory T-cell expansion with progression of amyotrophic lateral sclerosis: a study of humans and a transgenic mouse model. JAMA Neurol 2018; 75:681&#x2013;689.</Citation></Reference><Reference><Citation>Thonhoff JR, Beers DR, Zhao W, et al. Expanded autologous regulatory T-lymphocyte infusions in ALS: a phase I, first-in-human study. Neurol Neuroimmunol Neuroinflamm 2018; 5:e465.</Citation></Reference><Reference><Citation>Beers DR, Zhao W, Neal DW, et al. Elevated acute phase proteins reflect peripheral inflammation and disease severity in patients with amyotrophic lateral sclerosis. Sci Rep 2020; 10:15295.</Citation></Reference><Reference><Citation>Lunetta C, Maestri E, Sansone VA, et al. Serum C-reactive protein as a prognostic biomarker in amyotrophic lateral sclerosis. JAMA Neurol 2017; 74:660&#x2013;667.</Citation></Reference><Reference><Citation>Beers DR, Zhao W, Thonhoff JR, et al. Serum programmed cell death proteins in amyotrophic lateral sclerosis. Brain Behav Immun Health 2021; 12:100209.</Citation></Reference><Reference><Citation>Zhang YG, Wu S, Yi J, et al. Target intestinal microbiota to alleviate disease progression in amyotrophic lateral sclerosis. Clin Ther 2017; 39:322&#x2013;336.</Citation></Reference><Reference><Citation>Boddy SL, Giovannelli I, Sassani M, et al. The gut microbiome: a key player in the complexity of amyotrophic lateral sclerosis (ALS). BMC Med 2021; 19:13.</Citation></Reference><Reference><Citation>Blacher E, Bashiardes S, Shapiro H, et al. Potential roles of gut microbiome and metabolites in modulating ALS in mice. Nature 2019; 572:474&#x2013;480.</Citation></Reference><Reference><Citation>Burberry A, Wells MF, Limone F, et al. C9orf72 suppresses systemic and neural inflammation induced by gut bacteria. Nature 2020; 582:89&#x2013;94.</Citation></Reference><Reference><Citation>Clarke BE, Patani R. The microglial component of amyotrophic lateral sclerosis. Brain 2020; 143:3526&#x2013;3539.</Citation></Reference><Reference><Citation>Geloso MC, Corvino V, Marchese E, et al. The dual role of microglia in ALS: mechanisms and therapeutic approaches. Front Aging Neurosci 2017; 9:242.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>